http://rdf.ncbi.nlm.nih.gov/pubchem/reference/28487449

Outgoing Links

Predicate Object
contentType Journal Article
issn 2056-5623
issueIdentifier 1
pageRange FSO253-
publicationName Future Science OA
startingPage FSO253
bibliographicCitation Niraula S, Templeton AJ, Vera-Badillo F, Dodd A, Nugent Z, Joshua AM, Tannock IF. Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer. Future Sci OA. 2018 Jan;4(1):FSO253. PMID: 29255625; PMCID: PMC5729592.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a5381f93d5730e0029f2fcd93cc6235b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aef7374b07e47c3769149ac61128309b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1f3358af9e78a61954b333fa3e75c41d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9d5218fc870538f1c731b4a9468d839a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_901d787d2879cd1b2d7e26fa87a18685
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3addc25143974fe0cc204cbcc5bc9d18
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_14c172010c6b4effdc8c0889a01769c8
date 201801
identifier https://pubmed.ncbi.nlm.nih.gov/29255625
https://pubmed.ncbi.nlm.nih.gov/PMC5729592
https://doi.org/10.4155/fsoa-2017-0094
isPartOf https://portal.issn.org/resource/ISSN/2056-5623
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/44190
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68740
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7077
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983

Showing number of triples: 1 to 28 of 28.